Your browser doesn't support javascript.
loading
Blocking the TRAIL-DR5 Pathway Reduces Cardiac Ischemia-Reperfusion Injury by Decreasing Neutrophil Infiltration and Neutrophil Extracellular Traps Formation.
Wang, Xuance; Xie, Ran; Zhao, Dan; Wang, Guiling; Zhang, Lijie; Shi, Wei; Chen, Yanyan; Mo, Tingting; Du, Yuxin; Tian, Xuefei; Wang, Wanjun; Cao, Run; Ma, Yuanfang; Wei, Yinxiang; Wang, Yaohui.
Afiliação
  • Wang X; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Xie R; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Zhao D; The College of Medical Technology, Shangqiu Medical College, Shangqiu, 476000, P.R. China.
  • Wang G; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Zhang L; The First Affiliated Hospital, Henan University, Kaifeng, 475004, P.R. China.
  • Shi W; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Chen Y; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Mo T; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Du Y; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Tian X; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Wang W; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Cao R; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Ma Y; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Wei Y; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
  • Wang Y; Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, P.R. China.
Article em En | MEDLINE | ID: mdl-38900242
ABSTRACT

PURPOSE:

Acute myocardial infarction (AMI) is a leading cause of mortality. Neutrophils penetrate injured heart tissue during AMI or ischemia-reperfusion (I/R) injury and produce inflammatory factors, chemokines, and extracellular traps that exacerbate heart injury. Inhibition of the TRAIL-DR5 pathway has been demonstrated to alleviate cardiac ischemia-reperfusion injury in a leukocyte-dependent manner. However, it remains unknown whether TRAIL-DR5 signaling is involved in regulating neutrophil extracellular traps (NETs) release.

METHODS:

This study used various models to examine the effects of activating the TRAIL-DR5 pathway with soluble mouse TRAIL protein and inhibiting the TRAIL-DR5 signaling pathway using DR5 knockout mice or mDR5-Fc fusion protein on NETs formation and cardiac injury. The models used included a co-culture model involving bone marrow-derived neutrophils and primary cardiomyocytes and a model of myocardial I/R in mice.

RESULTS:

NETs formation is suppressed by TRAIL-DR5 signaling pathway inhibition, which can lessen cardiac I/R injury. This intervention reduces the release of adhesion molecules and chemokines, resulting in decreased neutrophil infiltration and inhibiting NETs production by downregulating PAD4 in neutrophils.

CONCLUSION:

This work clarifies how the TRAIL-DR5 signaling pathway regulates the neutrophil response during myocardial I/R damage, thereby providing a scientific basis for therapeutic intervention targeting the TRAIL-DR5 signaling pathway in myocardial infarction.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article
...